Lataa...
Natalizumab and progressive multifocal leucoencephalopathy
Current data suggest that as many as 1 in 1000 treated individuals may develop progressive multifocal leucoencephalopathy (PML) in concert with the use of natalizumab. Natalizumab was withdrawn in early 2005. The present paper provides a comprehensive description of PML and reviews the role of natal...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Group
2006
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1798374/ https://ncbi.nlm.nih.gov/pubmed/17038473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2006.058404 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|